David A. Siegel Cabaletta Bio, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 413,600 shares of CABA stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
413,600
Previous 471,500
12.28%
Holding current value
$1.13 Million
Previous $655,000
4.12%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CABA
# of Institutions
91Shares Held
77.1MCall Options Held
406KPut Options Held
90.9K-
Bain Capital Life Sciences Investors, LLC Boston, MA9.68MShares$26.5 Million4.41% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.83MShares$24.2 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.79MShares$18.6 Million0.01% of portfolio
-
Jennison Associates LLC6.02MShares$16.5 Million0.01% of portfolio
-
Cormorant Asset Management, LP Boston, MA5MShares$13.7 Million0.77% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $79.5M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...